Waters (WAT) Price Target Increased to $202.00 by Analysts at Bank of America

Waters (NYSE:WAT) had its target price boosted by Bank of America from $192.00 to $202.00 in a report published on Friday, November 10th. They currently have a neutral rating on the medical instruments supplier’s stock.

A number of other brokerages also recently commented on WAT. Cowen reissued a hold rating and issued a $190.00 price target on shares of Waters in a report on Friday, November 3rd. Barclays upped their price objective on Waters from $188.00 to $193.00 and gave the company an equal weight rating in a research note on Wednesday, October 25th. Citigroup restated a neutral rating and set a $180.00 price objective on shares of Waters in a research note on Wednesday, October 25th. Zacks Investment Research cut Waters from a buy rating to a hold rating in a research note on Thursday, October 26th. Finally, Robert W. Baird increased their price target on Waters from $196.00 to $199.00 and gave the stock an outperform rating in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $193.62.

Waters (WAT) traded down $2.12 during mid-day trading on Friday, reaching $195.68. The company’s stock had a trading volume of 332,200 shares, compared to its average volume of 514,031. Waters has a 1 year low of $133.35 and a 1 year high of $200.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 5.71 and a current ratio of 6.16. The stock has a market capitalization of $15,630.00, a P/E ratio of 27.22, a PEG ratio of 2.84 and a beta of 0.82.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, October 24th. The medical instruments supplier reported $1.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.74 by $0.03. The company had revenue of $565.58 million during the quarter, compared to the consensus estimate of $555.25 million. Waters had a return on equity of 23.61% and a net margin of 24.34%. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.57 earnings per share. equities analysts predict that Waters will post 7.42 earnings per share for the current fiscal year.

In other news, Director Thomas P. Salice sold 3,500 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $200.03, for a total value of $700,105.00. Following the completion of the sale, the director now owns 20,349 shares in the company, valued at $4,070,410.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rohit Khanna sold 26,913 shares of the stock in a transaction on Friday, October 27th. The stock was sold at an average price of $197.93, for a total value of $5,326,890.09. Following the sale, the senior vice president now owns 13,677 shares of the company’s stock, valued at $2,707,088.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,813 shares of company stock valued at $11,820,747. Corporate insiders own 5.07% of the company’s stock.

Several large investors have recently made changes to their positions in WAT. Oppenheimer Asset Management Inc. raised its holdings in Waters by 0.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 573 shares of the medical instruments supplier’s stock valued at $105,000 after buying an additional 2 shares in the last quarter. ETF Managers Group LLC bought a new position in Waters during the second quarter valued at about $106,000. Intellectus Partners LLC raised its holdings in Waters by 4.9% during the second quarter. Intellectus Partners LLC now owns 667 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 31 shares in the last quarter. First Manhattan Co. bought a new position in Waters during the second quarter valued at about $130,000. Finally, Edmond DE Rothschild Holding S.A. bought a new position in Waters during the second quarter valued at about $160,000. Institutional investors and hedge funds own 94.66% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/waters-corporation-wat-price-target-raised-to-202-00/1774421.html.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.